The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease

被引:35
作者
Boucher M.-P. [3 ]
Lefebvre C. [3 ]
Chapados N.A. [1 ,2 ]
机构
[1] Institut de recherche de l'Hôpital Montfort, Hôpital Montfort, 713 Montreal Road, Ottawa, K1K 0T2, ON
[2] School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, ON
[3] La Cite, Ottawa, ON
基金
加拿大自然科学与工程研究理事会;
关键词
Environmental contaminants; Liver; Rats; Steatosis;
D O I
10.1186/s40200-015-0218-2
中图分类号
学科分类号
摘要
Background: Non alcoholic fatty liver disease (NAFLD) results from alteration in lipid synthesis and elimination mechanisms such as very-low density lipoprotein (VLDL) production and de novo lipogenesis. Persistent organic pollutants (POPs) are chemicals that were mostly used historically as pesticides, solvents, flame retardant, and other applications. Among POPs, polychlorinated biphenyls (PCB) have been recognized to be of environmental and potential toxicologic concerns. Specifically, PCB126 could act as endocrine disruptors and has recently been associated with hepatic fat accumulation. The purpose of the study was to investigate the effects of PCB126 on the molecular development of NAFLD using hepatocyte and rat models. Methods: Hepatocytes were exposed to PCB 126 for 72 h and lipid accumulation in cells was quantified by Oil-Red-O. Rats were injected with a single dose of PCB126 or vehicle. Seven days later, liver triglycerides (TAG) content was measured along with protein quantification of hepatic microsomal triglyceride transfer protein (MTP), sterol regulatory element-binding protein 1c (SREBP1c) and diacylglycerol O-acyltransferase 2 (DGAT-2). Results: Exposure to PCB126 resulted in significant increases of lipid accumulation in hepatocytes (38 %, P <0.05) and hepatic TAG concentrations (64 %, P < 0.001) in rats compared to respective control groups. Rats with fatty livers depicted lower MTP (40 %, P < 0.02), higher SREBP1c (27 %, P < 0.05) and DGAT-2 (120 %, P < 0.02) protein content levels compared to Placebo group in rats. Conclusions: It seems that exposure to PCB126 has an important emerging role in the pathophysiology of NAFLD by 1) altering elimination mechanisms such as VLDL synthesis and secretion, through MTP; and 2) increasing hepatic TAG synthesis mechanisms through DGAT 2 and SREBP1c. © 2015 Boucher et al.
引用
收藏
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers
    Edens, M. A.
    Kuipers, F.
    Stolk, R. P.
    OBESITY REVIEWS, 2009, 10 (04) : 412 - 419
  • [22] Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring
    Long, Michelle T.
    Gurary, Ellen B.
    Massaro, Joseph M.
    Ma, Jiantao
    Hoffmann, Udo
    Chung, Raymond T.
    Benjamin, Emelia J.
    Loomba, Rohit
    LIVER INTERNATIONAL, 2019, 39 (04) : 740 - 747
  • [23] Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
    Valenzuela-Vallejo, Laura
    Sanoudou, Despina
    Mantzoros, Christos S.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [24] Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease
    Moon, Seung Hwan
    Hong, Sun-pyo
    Cho, Young Seok
    Noh, Tae Soo
    Choi, Joon Young
    Kim, Byung-Tae
    Lee, Kyung-Han
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (03) : 892 - 899
  • [25] Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease
    Hussain, Mazhar
    Babar, Muhammad Zafar Majeed
    Hussain, Muhammad Shahbaz
    Akhtar, Lubna
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2016, 32 (06) : 1396 - 1401
  • [26] Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice
    Rostama, Bahman
    Beauchemin, Megan
    Bouchard, Celeste
    Bernier, Elizabeth
    Vary, Calvin P. H.
    May, Meghan
    Houseknecht, Karen L.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (24) : 1 - 20
  • [27] Liver transplantation and non-alcoholic fatty liver disease
    Zezos, Petros
    Renner, Eberhard L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15532 - 15538
  • [28] Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease
    Zhang, Qiu-Zan
    Liu, Ying-Li
    Wang, Yan-Rong
    Fu, Li-Na
    Zhang, Jing
    Wang, Xiu-Ru
    Wang, Bang-Mao
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (03) : 2689 - 2694
  • [29] Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Ahsan, Farah
    Oliveri, Federico
    Goud, Harshit K.
    Mehkari, Zainab
    Mohammed, Lubna
    Javed, Moiz
    Althwanay, Aldanah
    Rutkofsky, Ian H.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [30] The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease
    Phrueksotsai, Susrichit
    Pinyopornpanish, Kanokwan
    Euathrongchit, Juntima
    Leerapun, Apinya
    Phrommintikul, Arintaya
    Buranapin, Supawan
    Chattipakorn, Nipon
    Thongsawat, Satawat
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (10) : 2952 - 2959